Lifang Yin
- Biomaterials top 0.5%
- Molecular Biology top 5%
- Pharmaceutical Science top 0.2%
- Biomedical Engineering top 2%
- Oncology top 5%
- Topics
- Nanoparticle-Based Drug Delivery (48 papers)RNA Interference and Gene Delivery (25 papers)Nanoplatforms for cancer theranostics (25 papers)
- Partner nations
- ChinaUnited StatesUnited Kingdom
In The Last Decade
Lifang Yin
110 papers receiving 4.4k citations
Hit Papers
Peers
Comparison fields: 5 of 156
- Biomaterials 1.6k
- Molecular Biology 1.6k
- Pharmaceutical Science 1.2k
- Biomedical Engineering 1.1k
- Oncology 567
Countries citing papers authored by Lifang Yin
This map shows the geographic impact of Lifang Yin's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Lifang Yin with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Lifang Yin more than expected).
Fields of papers citing papers by Lifang Yin
This network shows the impact of papers produced by Lifang Yin. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Lifang Yin. The network helps show where Lifang Yin may publish in the future.
Co-authorship network of co-authors of Lifang Yin
This figure shows the co-authorship network connecting the top 25 collaborators of Lifang Yin. A scholar is included among the top collaborators of Lifang Yin based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Lifang Yin. Lifang Yin is excluded from the visualization to improve readability, since they are connected to all nodes in the network.
All Works
| # | Work | Indexed citations |
|---|---|---|
| 1 | 3 | |
| 2 | 1 | |
| 3 | 0 | |
| 4 | 16 | |
| 5 | 0 | |
| 6 | 4 | |
| 7 | 36 | |
| 8 | 51 | |
| 9 | 15 | |
| 10 | 98 | |
| 11 | 5 | |
| 12 | 71 | |
| 13 | 28 | |
| 14 | 27 | |
| 15 | 51 | |
| 16 | 21 | |
| 17 | 50 | |
| 18 | 43 | |
| 19 | 25 | |
| 20 | Preparation and formulation optimization of silymarin sustained-release tablets. | 1 |
About Lifang Yin
Lifang Yin is a scholar working on Pharmaceutical Science, Biomaterials and Hepatology, having authored 120 papers that have together received 4.6k indexed citations. Recurring topics across this work include Nanoparticle-Based Drug Delivery (48 papers), RNA Interference and Gene Delivery (25 papers) and Nanoplatforms for cancer theranostics (25 papers). The work is most often cited by research in Pharmaceutical Science (1.2k citations), Biomaterials (1.6k citations) and Molecular Medicine (218 citations). Lifang Yin has collaborated with scholars based in China, United States and United Kingdom. Frequent co-authors include Wei He, Yaqi Lv, Imran Shair Mohammad, Lifang Fan, Jianping Zhou, Yiao Wang, Jin Zhu, Shumin Zhu, Ke Yang and Wei He. Their work appears in journals such as ACS Nano, Biomaterials and Scientific Reports.
Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.